Axsome Therapeutics

AXSM | NASDAQ | 9 Followers

$104.10

-2.02%

-$2.15

Overview Metrics Financials

Fair Price

$712.69

Undervalued by 57.8%

To display the fair price of a share, you need to be a member of Bulios Black.

Company Quality

Profitability Score

17/100

Solvency Score

45/100

Dividends

Dividends data currently unavailable.

Earnings

8/4/2025

in 50 days

$140M

Revenue est.

-1.00

EPS est.

My Notes

You haven't added any notes for this stock yet. Use this space to record your insights or strategies.

Profile

Healthcare

Sector

Biotechnology

Industry

Dr. Herriot Tabuteau M.D.

CEO

712

Employees

New York City

Headquarters

Country

Axsome Therapeutics, Inc. (AXSM) is a biotechnology company focused on the development and commercialization of innovative drugs for the treatment of various neurologic and psychiatric disorders. The company targets therapeutic areas such as depression, migraines, Alzheimer's disease, and other neurological conditions that have a significant impact on human health. Axsome Therapeutics aims to improve the quality of life for patients by offering novel and effective treatment options. With active research and clinical trials, the company has a promising pipeline of drugs that can have a positive impact on healthcare and the medical industry. Investing in Axsome Therapeutics, Inc. (AXSM) shares can be an attractive choice for investors who follow the biotechnology and pharmaceutical sectors and seek a company with the potential for significant growth and innovative treatment approaches.

Key Metrics TTM

Valuation

Market cap.

$5.1B

Enterprise Value

$5B

Price to Earnings

-18.28

Price to Sales

11.86

Price to Book

95.62

Price to Cash Flow

-43.34

Profitability

Return on Assets

-46.64%

Return on Equity

-363.79%

Return on Invested Capital

-76.54%

Gross Margin

91.49%

Operating Margin

-62.54%

Net Margin

-64.39%

Liquidity

Quick Ratio

1.96

Current Ratio

2.03

Cash Ratio

1.23

Inventory Turnover

2.25

Asset Turnover

0.72

Total Liabilities

$543M

Solvency

Debt to Assets

0.35

Debt to Equity

N/A

Interest Coverage

-34.66

Equity Ratio

0.09

Long-term Debt to Cap.

0.80

Altman Z-Score

2.52

Performance

Earnings Waterfall

Debt level and coverage

Earnings

Feed

There are no posts to show right now.